Nephrotect (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

The mixture supplies a balanced set of essential and non‑essential amino acids directly into the bloodstream. These amino acids act as building blocks for protein synthesis, replenish nitrogen stores, and support cellular metabolism, which is crucial when oral or enteral intake is insufficient or impossible.

The dose of Nephroprotect is individualized by the prescribing clinician based on the patient’s nutritional requirements, renal function, and overall clinical condition. Healthcare professionals calculate the appropriate volume and rate of infusion to meet the specific amino acid needs of each patient.

The safety of Nephroprotect in pregnancy or lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nephroprotect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nephroprotect offers a comprehensive amino acid profile specifically formulated for renal patients and those at risk of protein‑energy malnutrition. Compared with generic amino acid solutions, it includes a balanced mix of essential amino acids that may better support nitrogen balance and reduce the risk of metabolic complications in these populations.

Nephroprotect must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before administration, inspect for particulate matter or discoloration and use within the recommended time after opening.

Nephroprotect is administered intravenously, typically via a peripheral or central venous catheter. The infusion rate is determined by the prescribing clinician and may be adjusted based on the patient’s metabolic response, fluid balance, and electrolyte status.

Serious risks include anaphylactic or severe hypersensitivity reactions, severe metabolic acidosis, and bronchospasm. Patients should be monitored closely during infusion for any signs of allergic response, respiratory distress, or significant changes in acid‑base balance.

Nephroprotect should be avoided in patients with known hypersensitivity to any of its amino acid components. Caution is also advised for individuals with severe hepatic impairment, uncontrolled electrolyte disturbances, or those receiving incompatible intravenous solutions.